The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling-Reference-Cited by-同舟云学术

The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling

Published:2018-07-09 Issue: Volume:9 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

van Tok Melissa N.,Na Songqing,Lao Christopher R.,Alvi Marina,Pots Desirée,van de Sande Marleen G. H.,Taurog Joel D.,Sedgwick Jonathon D.,Baeten Dominique L.,van Duivenvoorde Leonie M.

Funder

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

European Research Council

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference50 articles.

1. Secukinumab, an Interleukin-17A inhibitor, in ankylosing spondylitis;Baeten;N Engl J Med,2015

2. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis;Mease;N Engl J Med,2015

3. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1;Mease;Ann Rheum Dis,2017

4. How cytokine networks fuel inflammation: interleukin-17 and a tale of two autoimmune diseases;Baeten;Nat Med,2013

5. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation;Langrish;J Exp Med,2005

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations;Expert Opinion on Biological Therapy;2024-08-02

2. Axial Disease in Psoriatic Arthritis: A Challenging Domain in Clinical Practice;Diagnostics;2024-07-30

3. Axial Spondyloarthritis: an overview of the disease;Rheumatology International;2024-04-30

4. T cells in the pathogenesis of axial spondyloarthritis;Joint Bone Spine;2023-12

5. Management of psoriatic arthritis: a consensus opinion by expert rheumatologists;Frontiers in Medicine;2023-11-30